Wells Fargo Downgrades enGene Therapeutics to Equal-Weight, Lowers Price Target to $2
Benzinga Newsdesk 5 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Wells Fargo analyst Yanan Zhu downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Equal-Weight and lowers the price target from $25 to $2.
Wells Fargo analyst Yanan Zhu downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Equal-Weight and lowers the price target from $25 to $2.